Citius Pharmaceuticals (CTXR) PT Raised to $10 at Dawson James
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CTXR Hot Sheet
Price: $0.56 -1.75%
Rating Summary:
3 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
3 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Dawson James analyst Jason Kolbert raised the price target on Citius Pharmaceuticals (NASDAQ: CTXR) to $10.00 (from $8.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citius Oncology presents LYMPHIR quality of life data at Berlin congress
- Procore Technologies, Inc (PCOR) PT Raised to $85 at Stifel
- Datadog (DDOG) PT Lowered to $285 at Rosenblatt
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
